Curing Lupus Atlas

Plain-language evidence map

What have people tried, and what happened?

Every serious attempt to fix lupus, sorted by outcome rather than by novelty. Most approved drugs control the disease without ending it. One approach has now done something none of them can — and one obvious experiment has never been run.

How we judge outcomes← See what causes it

How to read this page

"It works" hides the question that matters

Almost every lupus drug works in the sense that it lowers disease activity while you take it. The question this page sorts on is different: what happens when you stop?

  1. Remission without ongoing drugs — seen

    Some people have come off lupus drugs entirely and stayed well. This has never happened with any conventional lupus drug. The evidence is still early, mostly uncontrolled, and limited to severe refractory disease.

    1 on this page

  2. Controls it, does not cure it

    Works while you take it. Disease activity falls, but the underlying immune problem returns if treatment stops. This describes every approved lupus drug.

    3 on this page

  3. Being tested now

    Under active study with real but incomplete results. Promising is not the same as proven.

    7 on this page

  4. Nobody has tried it yet

    A specific, testable idea that follows from the evidence — and that no registered trial anywhere is currently running.

    1 on this page

  5. Tried and failed

    Tested properly and did not work. Kept visible because knowing what does not work is how a field stops repeating itself.

    3 on this page

This is not treatment advice. These verdicts describe what happened in studied groups, not what will happen to any individual. Several of these approaches are available only inside clinical trials. Decisions about treatment belong with a rheumatologist.

1 approach

Remission without ongoing drugs — seen

Some people have come off lupus drugs entirely and stayed well. This has never happened with any conventional lupus drug. The evidence is still early, mostly uncontrolled, and limited to severe refractory disease.

Rebuilding the immune system from scratch

CD19-directed CAR T-cell therapy

Remission without ongoing drugs — seen

A person's own T cells are re-engineered to hunt down and destroy every B cell in the body — including in tissue, not just blood — after which the immune system regrows from naive cells.

Goes after
The self-reactive B cells that sustain the disease.Immune cells that attack the body survive when they should be deleted
Where it stands
Prospective phase 1/2 trials complete; registrational trials running, including the first randomized comparison against standard care.

What happened

  • In the first published case series, people with severe refractory lupus stopped all lupus drugs and stayed in remission, with their defining autoantibodies disappearing.
  • A prospective basket trial reported no relapses at around a year of median follow-up, with normal vaccine antibody levels preserved and no severe immune-effector toxicity.
  • Tissue sampling showed B cells cleared from lymph nodes, not merely from blood — the likely reason this works where older antibody drugs did not.
  • The immune system regrows from naive B cells, and the chronic antiviral alarm signature collapses along the way.

What we still don't know

  • Durability beyond about five years. An older whole-immune-system reset relapsed in roughly half of people by three to five years — the cautionary benchmark.
  • Whether relapse comes from old surviving cells or newly made ones. Nobody has ever sequenced the cells at an autoimmune relapse.
  • Whether results hold outside young, recently diagnosed, refractory, antibody-rich patients — the group current trials are enriched for.
  • Long-term cancer risk from the engineering process, in people who do not have cancer.
  • Cost and access. Manufacturing is individual, slow, and expensive.
Sources (7)
  1. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trialMüller et al., Nature Medicine (2026) · nonrandomized interventional
  2. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upMüller et al., New England Journal of Medicine (2024) · case series
  3. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusMackensen et al., Nature Medicine (2022) · case series
  4. CD19-CAR T-cell therapy induces deep tissue depletion of B cellsTur et al., Annals of the Rheumatic Diseases (2025) · human mechanistic
  5. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLEWilhelm et al., JCI Insight (2024) · human mechanistic
  6. CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic reviewLi et al., Frontiers in Immunology (2026) · systematic review
  7. Breakfree-SLE: CC-97540 (BMS-986353; zola-cel) in active SLEClinicalTrials.gov NCT07015983 · trial registry

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

3 approaches

Controls it, does not cure it

Works while you take it. Disease activity falls, but the underlying immune problem returns if treatment stops. This describes every approved lupus drug.

A stronger antibody against B cells

Obinutuzumab

Controls it, does not cure it

An antibody infusion that depletes B cells more deeply than the older generation of the same drug class, given on top of standard treatment.

Goes after
The same self-reactive B cells, but with a drug rather than engineered cells.Immune cells that attack the body survive when they should be deleted
Where it stands
Approved for lupus nephritis; a further randomized trial has reported in non-kidney lupus.

What happened

  • A randomized trial in lupus kidney disease improved complete kidney response over standard therapy alone, leading to approval.
  • A later randomized trial reported benefit in lupus without kidney involvement as well.
  • It is now the benchmark any new approach has to beat, rather than a historical comparator.

What we still don't know

  • Whether treatment can ever be withdrawn. This is the central untested question for the whole drug class.
  • The improvement over the previous best option is real but modest — the gain in complete kidney response has moved only a few percentage points across fifteen years of drug development.
  • Secondary remission results in the non-kidney trial were not adjusted for multiple comparisons, so they should not be read as confirmatory.
Sources (3)
  1. Efficacy and Safety of Obinutuzumab in Active Lupus NephritisFurie et al., New England Journal of Medicine (2025) · randomized controlled trial
  2. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus ErythematosusALLEGORY trial, New England Journal of Medicine (2026) · randomized controlled trial
  3. GAZYVA (obinutuzumab) prescribing informationU.S. FDA prescribing information (revised 2025) · guideline or regulatory

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Switching off the false antiviral alarm

Anifrolumab (type I interferon receptor blockade)

Controls it, does not cure it

A monthly antibody that blocks the receptor for interferon, quieting the chronic antiviral response that drives inflammation.

Goes after
The interferon amplifier.An antiviral alarm that never switches off
Where it stands
Approved and in routine use; a subcutaneous version has now succeeded in phase 3.

What happened

  • One phase 3 trial met its primary endpoint; an earlier trial using a different endpoint did not — both results belong in the interpretation.
  • A subcutaneous formulation succeeded in a further randomized phase 3 trial.
  • Disease activity, skin involvement, and steroid requirements improve while treatment continues.

What we still don't know

  • It barely shifts the underlying autoantibodies. It manages the consequence rather than the cause.
  • The interferon signature has never been validated as a tool for deciding who should get it — and in an earlier failed drug, low-interferon patients responded better.
  • No evidence exists that benefit persists after stopping.
Sources (4)
  1. Trial of Anifrolumab in Active Systemic Lupus ErythematosusMorand et al., New England Journal of Medicine (2020) · randomized controlled trial
  2. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialFurie et al., Lancet Rheumatology (2019) · randomized controlled trial
  3. Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 StudyManzi et al., Arthritis & Rheumatology (2026) · randomized controlled trial
  4. SAPHNELO (anifrolumab-fnia) prescribing informationU.S. FDA prescribing information (revised April 2026) · guideline or regulatory

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Cutting off the survival signal for B cells

Belimumab and telitacicept (BAFF/APRIL blockade)

Controls it, does not cure it

B cells depend on survival factors to persist. These drugs soak up those factors, so self-reactive B cells are less likely to survive.

Goes after
The support system that keeps self-reactive B cells alive.Immune cells that attack the body survive when they should be deleted
Where it stands
Belimumab approved for SLE and lupus nephritis; a dual-target agent has reported positive phase 3 results.

What happened

  • Randomized trials established benefit on composite disease-activity endpoints and in kidney disease.
  • A newer agent blocking two survival factors at once reported a positive phase 3 result.

What we still don't know

  • It reduces B-cell survival but does not eliminate the lineage, and it does not produce drug-free remission.
  • Dosing is indefinite.
  • For the newer dual-target agent, pivotal evidence is geographically concentrated and global confirmation is not yet peer reviewed.
Sources (4)
  1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialNavarra et al., The Lancet (2011) · randomized controlled trial
  2. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisFurie et al., New England Journal of Medicine (2020) · randomized controlled trial
  3. BENLYSTA (belimumab) prescribing informationU.S. FDA prescribing information (revised June 2025) · guideline or regulatory
  4. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosusvan Vollenhoven et al., New England Journal of Medicine (2025) · randomized controlled trial

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

7 approaches

Being tested now

Under active study with real but incomplete results. Promising is not the same as proven.

Going after the hidden antibody factories too

CD19 plus BCMA-directed cell therapy

Being tested now

Adds a second target so the engineered cells also reach long-lived antibody-producing cells, which survive B-cell-only treatment.

Where it stands
Phase 1 trial reported; no randomized comparison against single-target therapy exists.

What happened

  • A phase 1 trial of co-infusion reported remission in most participants with only mild infusion toxicity.
  • The same work confirmed that long-lived plasma cells do persist after single-target treatment — the reason for adding the second target.
  • In one person who relapsed after single-target treatment, switching to the plasma-cell target re-induced remission.

What we still don't know

  • Whether the added benefit is worth the added risk. Removing these cells also removes protective antibodies built up over a lifetime.
  • Which patients actually need it. Most people appear to do well without it, so universal use is hard to justify.
  • No randomized comparison against single-target therapy has been run.
Sources (2)
  1. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trialFeng et al., Nature Medicine (2025) · nonrandomized interventional
  2. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsMüller et al., Nature Medicine (2025) · case report

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Off-the-shelf drugs against the antibody factories

BCMA T-cell engagers and daratumumab

Being tested now

Rather than engineering cells for each patient, these are ready-made drugs — borrowed from myeloma treatment — that attack plasma cells directly.

Goes after
The long-lived antibody factories, without individual manufacturing.Antibody factories that hide where drugs cannot reach
Where it stands
Single case reports and one single-arm phase 2 trial.

What happened

  • A single patient with refractory lupus went into remission on a BCMA-directed T-cell engager.
  • A single-arm phase 2 trial of a plasma-cell-directed antibody produced partial disease control.

What we still don't know

  • Effects were not durable after treatment stopped, which suggests partial depletion is not enough.
  • How deep depletion has to go before it matters. No threshold has been established.
  • Evidence is one case report plus one uncontrolled trial — far weaker than the cell-therapy evidence.
Sources (2)
  1. Teclistamab-Induced Remission in Refractory Systemic Lupus ErythematosusAlexander et al., New England Journal of Medicine (2024) · case report
  2. Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trialOstendorf et al., Nature Communications (2026) · nonrandomized interventional

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Making the treatment inside the body

In vivo lipid-nanoparticle mRNA CAR-T

Being tested now

Instead of removing cells, engineering them in a facility, and infusing them back, an injection instructs the body to make the engineered cells itself.

Goes after
The same B-cell target, but without the manufacturing that makes reset therapy inaccessible.Immune cells that attack the body survive when they should be deleted
Where it stands
First-in-human reports in a handful of patients.

What happened

  • A small number of people with refractory lupus have been treated, with early signals of B-cell depletion.

What we still don't know

  • Whether it achieves the same depth of tissue depletion as manufactured cells — the thing that appears to make the difference.
  • No durable drug-free remission data exist. This is years behind on durability.
  • Whether the access advantage survives real-world pricing.
Sources (1)
  1. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus ErythematosusNew England Journal of Medicine correspondence (2025) · case series

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Turning the overactive alarm back down

TLR7/8 inhibitors

Being tested now

Small molecules that block the sensor implicated by the rare genetic causes — the first lupus drug class to come directly out of genetics.

Where it stands
Phase 2 complete in skin lupus; the decisive phase 3 has not reported.

What happened

  • The class reproducibly suppresses interferon-linked laboratory readings, confirming it engages the intended target in people.
  • A phase 2 trial met a dose-response endpoint in skin lupus.

What we still don't know

  • The signal in whole-body lupus was weaker than in skin, and the effect sizes have been released only by press announcement.
  • The largest systemic trial of the class missed its primary dose-response objective.
  • No trial has enrolled confirmed carriers of the genetic variants this class was designed around — the group with the clearest rationale.
  • Engaging a pathway is not the same as showing the disease depends on it.
Sources (2)
  1. TLR7 gain-of-function genetic variation causes human lupusBrown et al., Nature (2022) · human mechanistic
  2. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupusDavid et al., Journal of Experimental Medicine (2024) · human mechanistic

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Replacing the missing cleanup enzyme

Engineered DNase biologics

Being tested now

Supplies a working version of the enzyme that clears DNA debris, for people who either lack it or make antibodies that block it.

Where it stands
First human case reported; a phase 1b basket study is registered.

What happened

  • One patient with inherited enzyme deficiency showed rapid clinical and laboratory improvement — the first human demonstration for this class.
  • A next-generation version has entered a registered early-phase study in lupus and rheumatoid arthritis.

What we still don't know

  • That first treatment had to be stopped when the patient developed antibodies against the drug. That is the central obstacle for enzyme replacement.
  • An earlier, cruder enzyme of this type failed decades ago, and a later attempt failed when given to unselected patients — selection looks essential.
  • It is mechanistically precise but aimed at chronic control, not cure.
  • A registry entry is not a result. No efficacy data exist yet.
Sources (3)
  1. Targeted Degradation of NETs in Lupus with DNASE1L3 DeficiencyNew England Journal of Medicine correspondence (2026) · case report
  2. LIBERATE-I: a phase 1b basket study of an engineered DNase in autoimmune diseaseClinicalTrials.gov registry record NCT07237659 · trial registry
  3. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosusHartl et al., Journal of Experimental Medicine (2021) · human mechanistic

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Restoring the immune system's brakes

Low-dose interleukin-2

Being tested now

Small doses of an immune signalling protein that selectively expand regulatory T cells — the cells that damp down immune responses.

Goes after
The shortfall in regulatory T cells.The immune system's brakes are worn
Where it stands
Phase IIb randomized trial reported.

What happened

  • A phase IIb trial found improvement over control, with a dose-dependent effect on regulatory T cells.

What we still don't know

  • An earlier randomized trial of the same concept missed its primary endpoint.
  • Benefit fades when dosing stops — it rebalances rather than retrains the immune system.
  • No confirmatory phase 3 result exists.
Sources (1)
  1. Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialNature Communications (2026) · randomized controlled trial

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Cooling down overactive immune cell metabolism

Sirolimus and related metabolic agents

Being tested now

Repurposed transplant and metabolic drugs that lower the metabolic activity keeping T cells switched on.

Goes after
The altered metabolism in T cells.Immune cells running their engines too hot
Where it stands
A placebo-controlled trial has been presented at a conference but not published.

What happened

  • A placebo-controlled trial reported a substantial improvement over placebo — the first positive controlled result for this approach.
  • An earlier randomized trial of a different metabolic agent was also positive.

What we still don't know

  • The headline result exists only as a conference presentation. Until it is published in full and peer reviewed, it cannot be treated as established, and this site does not cite it as a source.
  • Single country, short duration, and the earlier supporting trial was never independently replicated.
No published source yet

The strongest evidence here has been presented at a conference but not published in full. This site does not cite unpublished results as sources.

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

1 approach

Nobody has tried it yet

A specific, testable idea that follows from the evidence — and that no registered trial anywhere is currently running.

Protecting the rebuild after a reset

Post-CAR-T BAFF/APRIL blockade at B-cell return

Nobody has tried it yet

When B cells start coming back after cell therapy, survival-factor levels surge — which may be exactly the window where self-reactive cells get rescued. Blocking those factors during the rebuild might make remission permanent.

Goes after
The moment the immune system rebuilds itself, rather than the cells that caused the original disease.Immune cells that attack the body survive when they should be deleted · Antibody factories that hide where drugs cannot reach
Where it stands
No registered trial anywhere. This site has published a protocol concept for it.

What happened

  • Nothing yet — this is a proposal, listed here because it is the clearest gap the evidence points to.
  • The underlying biology is established: excess survival factor rescues self-reactive B cells that should be deleted, and those factors do surge after reset therapy.
  • In the one deeply studied relapse, inflammatory signals were rising months before B cells returned and long before disease came back — suggesting there is a window to act in.
  • Ordinary blood tests failed to detect the coming relapse in every characterised case.

What we still don't know

  • Earlier versions of this idea, after the older antibody drugs, missed their primary endpoints.
  • Stacking immune suppression after a reset carries a real infection risk, and could delay recovery of normal immunity and vaccine responses.
  • Persistent inflammatory signalling may be the more proximal driver, in which case blocking survival factors would target the wrong node.
Sources (3)
  1. Single-cell profiling of the first characterised SLE relapse after CD19 CAR-T therapyAnoshkin et al., medRxiv preprint (2026) — not peer reviewed · preprint
  2. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosusvan Vollenhoven et al., New England Journal of Medicine (2025) · randomized controlled trial
  3. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trialFeng et al., Nature Medicine (2025) · nonrandomized interventional

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

3 approaches

Tried and failed

Tested properly and did not work. Kept visible because knowing what does not work is how a field stops repeating itself.

The first attempt at removing B cells

Rituximab

Tried and failed

The original B-cell-depleting antibody. It works in other autoimmune diseases, and it is still used off-label in lupus — but it failed its randomized trials.

Goes after
Self-reactive B cells, using the first generation of the technology.Immune cells that attack the body survive when they should be deleted
Where it stands
Two randomized trials missed their primary endpoints; still used off-label in refractory disease.

What happened

  • A randomized trial in non-kidney lupus did not meet its primary endpoint.
  • The companion trial in lupus kidney disease also missed its primary endpoint.

What we still don't know

  • Why it failed while deeper depletion succeeds. The leading explanation is that it clears B cells from blood but leaves them in tissue.
  • Trial design of that era — heavy background steroids, endpoints since criticised — may have masked a real effect.
  • The failure is important context, not proof that the target was wrong: it is the reason 'B cells matter' does not imply 'any B-cell drug works'.
Sources (2)
  1. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosusMerrill et al., Arthritis & Rheumatism (2010) — EXPLORER · randomized controlled trial
  2. B-cell depletion in the treatment of lupus nephritisGregersen & Jayne, Nature Reviews Nephrology (2012) · systematic review

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Preventing lupus before it starts

Hydroxychloroquine in incomplete lupus

Tried and failed

People with some lupus features but not enough for a diagnosis were given the standard lupus drug early, to see whether it would stop them progressing. It did not.

Goes after
The transition from early immune abnormality to diagnosed disease.
Where it stands
The first true prevention trial in lupus. Completed and negative.

What happened

  • Hydroxychloroquine did not delay progression to classified lupus compared with placebo.
  • It overturns an earlier retrospective report that had suggested a preventive effect.
  • The field is therefore left with no validated way to prevent lupus.

What we still don't know

  • The trial may have been testing the wrong population rather than the wrong drug: far fewer participants progressed than expected, leaving little room to show an effect.
  • This says nothing about hydroxychloroquine in diagnosed lupus, where its role is well established and unchanged.
  • Prevention is not dead as an idea — but a way to identify who will actually progress has to come first.
Sources (2)
  1. A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete LupusOlsen et al., Arthritis & Rheumatology (2026) · randomized controlled trial
  2. Development of autoantibodies before the clinical onset of systemic lupus erythematosusArbuckle et al., New England Journal of Medicine (2003) · case control

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Teaching the immune system to stand down

Tolerogenic peptides

Tried and failed

Small protein fragments designed to retrain the immune system to stop attacking a specific self target — the most intuitive idea for a cure, and a consistent twenty-year failure.

Goes after
The self-reactivity itself, without removing any cells.Immune cells that attack the body survive when they should be deleted
Where it stands
Multiple phase 3 failures across different agents.

What happened

  • Trials of agents designed to induce tolerance to double-stranded DNA missed their endpoints.
  • A second tolerogenic peptide with a different design also missed its primary endpoint.
  • The pattern spans several agents and two decades, which makes it much harder to attribute to any one trial's design.

What we still don't know

  • Whether the concept is wrong or whether the delivery was. Newer tolerance approaches use different technology and have not been tested at scale in lupus.
  • These agents targeted one antibody specificity at a time, which may be too narrow for a disease with many.
Sources (2)
  1. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trialCardiel et al., Arthritis & Rheumatism (2008) · randomized controlled trial
  2. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosusUrowitz et al., Lupus Science & Medicine (2015) · randomized controlled trial

Last reviewed 2026-08-05 · agent-assisted draft, not domain-reviewed

Where this leaves the field

The gap is no longer "does anything work?"

It is whether the one approach that has produced drug-free remission holds up over five years, in ordinary patients rather than selected ones, and whether the immune system can be protected while it rebuilds itself. Those are answerable questions. Some of the studies that would answer them are running; at least one is not.

The research portfolio behind thisTherapies & trials in detail